Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial

NCT ID: NCT03151603

Last Updated: 2019-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

398 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-03

Study Completion Date

2019-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is well known that "over-treatment" of straightforward infections should be avoided as far as possible. Evidence-based data on non antibiotic treatment options for common conditions are therefore needed urgently. This randomised-controlled double blind trial examines whether initial herbal treatment with Uva Ursi, and antibiotic treatment only if symptoms persist, reduces antibiotic consumption in uncomplicated urinary tract infections (UTI) without a negative effect on symptom course and rate of recurrent UTIs. In total, 430 patients presenting with typical UTI symptoms will be included by their GPs and receive randomised either herbal treatment with uva ursi (antibiotics only if symptoms persist), or initial antibiotic treatment. Patients record symptom severity and drug intake in a diary and complete a final questionnaire after 28 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Uva Ursi

placebo to fosfomycin: 3 g granules orally 1x1 (day 0)

and

Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days

Group Type EXPERIMENTAL

Arctuvan

Intervention Type DRUG

application of a herbal drug

Placebo to Fosfomycin

Intervention Type DRUG

application of Placebo to Fosfomycin

fosfomycin

fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),

and

placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days

If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test.

Group Type ACTIVE_COMPARATOR

Fosfomycin

Intervention Type DRUG

application of an antibiotic drug

Placebo to Arctuvan

Intervention Type DRUG

application of Placebo to Arctuvan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arctuvan

application of a herbal drug

Intervention Type DRUG

Fosfomycin

application of an antibiotic drug

Intervention Type DRUG

Placebo to Arctuvan

application of Placebo to Arctuvan

Intervention Type DRUG

Placebo to Fosfomycin

application of Placebo to Fosfomycin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women (18-75 years) with suspected UTI
* at least two symptoms of UTI (dysuria, urgency of micturition, frequency, lower abdominal pain)
* Written informed consent

Exclusion Criteria

* signs of complicated UTI (e. g. temperature \> 38°C, loin tenderness)
* conditions that may lead to complicated infections (i.e. renal diseases, patients with urinary catheter)
* pregnancy/ breastfeeding
* current self-medication with UU preparations e.g. z.B. Cystinol®, Uvalysat®, Arctuvan®
* antibiotic use in the last 7 days
* previous UTI in the past 2 weeks
* history of pyelonephritis
* contraindications for trial drugs
* serious diseases
* inability to understand trial Information
* current participation in another clinical trial or participation in another clinical trial within the last 4 weeks
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Goettingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Karsten Gavenis

Quality Assurance Staff Unit Clinical Trials

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eva Hummers-Pradier, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Göttingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hausarztpraxis Dr. Raby

Achim, , Germany

Site Status

General Practice Aden

Braunschweig, , Germany

Site Status

General Practice Scheffer

Braunschweig, , Germany

Site Status

General Practice Coutelle

Bremen, , Germany

Site Status

General Practice Schelp

Bremen, , Germany

Site Status

General Practice Dickow

Burgwedel, , Germany

Site Status

General Practice Kiwit-Putzer

Burgwedel, , Germany

Site Status

Praxis Zietz

Celle, , Germany

Site Status

General Practice Kutzsche

Emmerthal, , Germany

Site Status

Praxis Dr. Bahr

Gieboldehausen, , Germany

Site Status

General Practice Müller

Gillersheim, , Germany

Site Status

Institute of General Medicine, University Medical Center Goettingen

Göttingen, , Germany

Site Status

Praxisgemeinschaft Jacob / Kling

Göttingen, , Germany

Site Status

General Practice Keske

Göttingen, , Germany

Site Status

General Practice Koch

Göttingen, , Germany

Site Status

General Practice Kolb

Göttingen, , Germany

Site Status

General Practice Lang

Göttingen, , Germany

Site Status

General Practice Lückerath

Göttingen, , Germany

Site Status

Praxis Dr. Egner

Hanover, , Germany

Site Status

Institute of General Medicine, MHH Hannover

Hanover, , Germany

Site Status

General Practice Barth

Hanover, , Germany

Site Status

General Practice Löber

Hardegsen, , Germany

Site Status

Gemeinschaftspraxis Dres Schlesier / Eckhardt

Heilbad Heiligenstadt, , Germany

Site Status

Gemeinschaftspraxis Hartleb / Stöcking

Heilbad Heiligenstadt, , Germany

Site Status

Praxis Dr. Koch

Heilbad Heiligenstadt, , Germany

Site Status

Praxisgemeinschaft Seitz / Eckert

Herzberg, , Germany

Site Status

General Practice Wilde

Hildesheim, , Germany

Site Status

Praxisgemeinschaft Stoltz / Raddatz

Höxter, , Germany

Site Status

General Practice Beverungen

Höxter, , Germany

Site Status

Gemeinschaftspraxis Kasperczyk / Schindewolf-Lensch

Isernhagen-Süd, , Germany

Site Status

General Practice Franz

Katlenburg-Lindau, , Germany

Site Status

Praxis Dr. Ohlendorf

Langenhagen, , Germany

Site Status

General Practice Ertel

Langwedel, , Germany

Site Status

General Practice Wehrbein

Lemförde, , Germany

Site Status

General Practice Lindenblatt

Neustadt, , Germany

Site Status

Hausarztzentrum Nörten

Nörten-Hardenberg, , Germany

Site Status

General Practice Preiskorn

Rehburg-Loccum, , Germany

Site Status

General Practice Meier-Ahrens

Rosdorf, , Germany

Site Status

General Practice Woitschek

Salzgitter, , Germany

Site Status

General Practice Beulshausen

Sattenhausen, , Germany

Site Status

General Practice Schulte

Scheeßel, , Germany

Site Status

General Practice Böttcher

Schwanewede, , Germany

Site Status

General Practice Albrecht

Springe, , Germany

Site Status

General Practice Wolf

Uslar, , Germany

Site Status

General Practice Schmiemann

Verden an der Aller, , Germany

Site Status

General Practice Annweiler

Waake, , Germany

Site Status

General Practice Stegemann

Wunstorf, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Gagyor I, Hummers E, Schmiemann G, Friede T, Pfeiffer S, Afshar K, Bleidorn J. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect. 2021 Oct;27(10):1441-1447. doi: 10.1016/j.cmi.2021.05.032. Epub 2021 Jun 7.

Reference Type DERIVED
PMID: 34111592 (View on PubMed)

Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gagyor I. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x.

Reference Type DERIVED
PMID: 29970072 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

01579

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Urine Alkalinization for UTI in Women: RCT
NCT07202832 NOT_YET_RECRUITING NA
Urell and Pregnancy
NCT01818180 TERMINATED NA
The INSPIRE-ASP UTI Trial
NCT03697096 COMPLETED NA
Nutraceutical Efficacy for rUTI
NCT03395288 TERMINATED PHASE2/PHASE3